Robert Peters

Company: Ensoma

Job title: Chief Scientific Officer

Seminars:

Envisioning the Future Evolution of In Vivo Hematopoietic Stem Cell Engineering & Gene Editing Treatments 8:30 am

Establishing in vivo HSC engineering approaches by leveraging validated biology from ex vivo therapeutics to eliminate patient and manufacturing burdens and expand treatable patient populations Combining large gene insertions and lineage-specific control in vivo to enable multicellular interventions to diversify treatment opportunities Evaluating in vivo HSC engineering opportunities in gene editing methods, including Cas9, base…Read more

day: Day Two